provides

Calidi Biotherapeutics Provides Required NYSE American Disclosure

May 22, 2026 18:00 ET  | Source: Calidi Biotherapeutics, Inc SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics,…

20 hours ago

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

May 15, 2026 20:19 ET  | Source: Regeneron Pharmaceuticals, Inc. The trial did not reach statistical significance for the primary…

1 week ago

GLG Provides Expert Insights on Bloomberg’s ASKB

GLG and Bloomberg Terminal® clients can now access the premium research provider's unblinded expert transcripts directly via Bloomberg's new conversational…

2 weeks ago

Sankaty Jet Capital Provides $68 Million Debt Facility to Wheels Up

Sankaty Jet Capital, a wholly owned subsidiary of AIP Capital, has committed capital through a new secured mezzanine facilitySTAMFORD, Conn.…

2 weeks ago

ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome…

2 weeks ago

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~…

3 weeks ago

Nicox Provides Full Year 2025 Financial Results and Corporate Update

April 30, 2026 01:30 ET  | Source: NICOX SA Press Release Nicox Provides Full Year 2025 Financial Results and Corporate…

4 weeks ago

CORRECTION — Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led…

4 weeks ago

Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy

AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company…

1 month ago

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – –…

2 months ago